Valneva obtains exclusive worldwide license for LimmaTech's S4V Shigella vaccine candidate and adds an attractive Phase 2 clinical asset to Valneva's R&D pipeline LimmaTech to receive upfront payment, is eligible for future milestone and royalty payments, and will collaborate on S4V clinical development through Phase 2 Valneva will host a live webcast on this announcement at 3 p.m. CEST/9 a.m. EDT today. Please refer to this link: https://edge.media-server.com/mmc/p/ck932u2n Saint-Herblain (France) and Schl ...

Valneva to receive up to $41.3 million from CEPI and the European Union to expand access to chikungunya vaccine, IXCHIQ® Funding will support clinical trials in vulnerable groups, such as children and pregnant women Partnership will also support technology transfer to an additional manufacturer to supply IXCHIQ® to Asian LMICs IXCHIQ® is already approved for use in adults 18 years of age and older in the U.S., Canada and Europe CEPI will provide Valneva up to U.S. $41.3 million of additional funding over th ...

Significance of the IXCHIQ Vaccine Expanding Market Potential An additional marketing authorization application is under review by the Brazilian Health Regulatory Agency to make the vaccine available in certain low- and middle-income countries, with a potential approval in 2024. Valneva's latest approval from the EC turns out to be in favor of market growth. Valneva SE (VALN) recently announced that the European Commission (EC) has given it the marketing authorization for Valneva's single-dose Chikungunya v ...

Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva, commented, "The EC approval marks a crucial milestone toward making this vaccine available to as many European citizens as possible. In recent years, climate change has caused the Aedes mosquito, a known carrier of chikungunya and dengue viruses, to spread to areas in Europe that were previously unaffected. It is critical to provide a vaccine solution not only to European travelers going to endemic chikungunya areas, such as South America or Afr ...

Saint Herblain (France), July 1, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Commission (EC) has granted marketing authorization in Europe for Valneva's single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The approval was unanimously endorsed by Member States following a stringent assessment by the European Medicines Agency (EMA)1. The EC decision marks ...

Ms. Danièle Guyot-Caparros was appointed to Valneva's Board of Directors for a three-year term. Ms. GuyotCaparros has a proven track record in finance and business operations. She started her career in Audit and Corporate Finance with PWC specializing in the Chemical/Pharma Industry. In 1992, she joined RhônePoulenc-Rorer (later Aventis and Sanofi) where she held several senior finance positions (CFO Global R&D, CFO Europe, Group Planning). She also held responsibilities in business development, pricing, an ...

Valneva SE (VALN) , a specialty vaccine company, has achieved a significant milestone with the approval of its single-dose chikungunya vaccine, IXCHIQ, by Health Canada. This approval follows the FDA's nod in November 2023 as well as the European Medicines Agency's recent recommendation for marketing authorization in Europe. Also known as CHIKV, Chikungunya is a mosquito-borne viral disease spread by the bites of infected female Aedes mosquitoes. It commonly causes fever, severe joint pain, muscle pain, hea ...

Dr. Richard Hatchett, Chief Executive Officer of CEPI, commented: "Health Canada's approval of IXCHIQ® represents another significant advance in the fight against the debilitating chikungunya virus. Accelerated by climate change, the size and frequency of chikungunya outbreaks are increasing, with hundreds of thousands of cases already reported so far this year in the Americas, South Asia, and Africa. This is why CEPI, with its partners Valneva and the European Commission, are working to expand access to th ...

Saint-Herblain (France), June 24, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has approved IXCHIQ®, Valneva's single-dose vaccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. This decision marks the second approval the Company has received for IXCHIQ® following approval from the U.S. Food and Drug Administration (FDA) in November 2023. The European Medicines Agency (EMA) also ...

Saint-Herblain (France), June 5, 2024 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company ("the Company"), today announced the availability of documentation for its Combined General Meeting ("the Meeting") to be held on June 26, 2024 at 2:00 p.m. CEST at the Sofitel Lyon Bellecour Hotel, 20 quai du Docteur Gailleton, 69002 Lyon (France). The Preliminary Notice of Meeting – including the agenda, the draft resolutions proposed by the Board of Directors, and instructions for participation and vo ...